Study provides new insights on how diabetes drug works

Many individuals with type 2 diabetes produce abnormally low levels of a gut hormone called GLP-1, which normally stimulates insulin release from the pancreas.

Now a new study shows that GLP-1 production by special cells in the gut known as L-cells can be restored in patients with recent onset type 2 diabetes following three to 12 months of treatment with liraglutide, a drug that is similar to native GLP-1.

"This study shows that chronic liraglutide therapy induces a robust enhancement of GLP-1 secretion by the body that may hold implications for the of this medication in patients," said Dr. Ravi Retnakaran, senior author of the Diabetes, Obesity and Metabolism study.


Explore further

Liraglutide doesn't affect gastric emptying in type 1 diabetes

More information: Thomas Forst et al, Effects on α- and β-cell function of sequentially adding empagliflozin and linagliptin to therapy in people with type 2 diabetes previously receiving metformin: An exploratory mechanistic study, Diabetes, Obesity and Metabolism (2017). DOI: 10.1111/dom.12838
Provided by Wiley
Citation: Study provides new insights on how diabetes drug works (2017, February 10) retrieved 24 August 2019 from https://medicalxpress.com/news/2017-02-insights-diabetes-drug.html
This document is subject to copyright. Apart from any fair dealing for the purpose of private study or research, no part may be reproduced without the written permission. The content is provided for information purposes only.
3 shares

Feedback to editors

User comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more